Physician profile
Emily Pfeifer
NPI 1093079055
$1,061.53
in general payments reported to CMS, 2019-2025
11 companies · $399 in 2025
The $399 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38.21 · 2020: $57.14 · 2023: $275 · 2024: $292 · 2025: $399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $916 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $916.18 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $337.48 | 2019-2025 | Enbrel, Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $311.57 | 2023-2025 | |
| Horizon Therapeutics Plc | $153.35 | 2020-2023 | Krystexxa |
| Ucb, INC. | $67.17 | 2025 | Bimzelx |
| Alexion Pharmaceuticals, INC. | $50.00 | 2024 | Ultomiris |
| Abbvie INC. | $43.94 | 2023-2024 | |
| Janssen Biotech, INC. | $28.92 | 2020-2023 | Tremfya |
| Ani Pharmaceuticals, INC. | $21.55 | 2023 | Purified Cortrophin Gel |
| E.R. Squibb & Sons, L.L.C. | $18.36 | 2025 | Orencia |
| Takeda Pharmaceuticals U.S.A., INC. | $15.38 | 2019 | |
| Genzyme Corporation | $13.81 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Pfeifer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.